Crystalline form of Remdesivir
US11377456B2 · kind B2 · utility
13Cited by
5References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2021 |
| Grant date | Jul 5, 2022 |
| Priority date | — |
| Expiry date | May 25, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, including remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods of treating viral infections using the same, and in particular, a viral infection caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.